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Abstract
Purpose Graves’ orbitopathy (GO) is
associated with changes in the appearance of
the eyes and visual dysfunction. Patients
report feeling socially isolated and unable to
continue with day-to-day activities. This
study aimed at investigating the
demographic, clinical, and psychosocial
factors associated with quality of life in
patients presenting for orbital decompression
surgery.
Methods One-hundred and twenty-three
adults with GO due for orbital
decompression at Moorﬁelds Eye Hospital
London were recruited prospectively. Clinical
measures including treatment history,
exophthalmos, optic neuropathy, and diplopia
were taken by an ophthalmologist.
Participants completed psychosocial
questionnaires, including the Graves’
Ophthalmopathy Quality of Life Scale
(GO-QOL), the Hospital Anxiety and
Depression Scale, and the Derriford
Appearance Scale. Hierarchical multiple
regression analyses were used to identify
predictors of quality of life.
Results Higher levels of potential cases of
clinical anxiety (37%) and depression (26%)
were found in this study sample than in
patients with other chronic diseases or facial
disﬁgurements. A total of 55% of the variance
in GO-QOL visual function scores was
explained by the regression model; age,
asymmetrical GO and depressed mood were
signiﬁcant unique contributors. In all, 75% of
the variance in GO-QOL appearance scores
was explained by the regression model;
gender, appearance-related cognitions and
depressed mood were signiﬁcant unique
contributors.
Conclusion Appearance-related quality of
life and mood were particularly affected in
this sample. Predominantly psychosocial
characteristics were associated with quality of
life. It is important when planning surgery
for patients that clinicians be aware of factors
that could potentially inﬂuence outcomes.
Eye advance online publication, 22 May 2015;
doi:10.1038/eye.2015.76
Introduction
Graves’ orbitopathy (GO) is an autoimmune
thyroid disorder that affects the eyes. An
estimated 25–50% of patients with Graves’
disease develop GO.1 The most common early
symptom of GO is a noticeable change in the
appearance of the eyes, including redness of the
eyelids, swelling, and disﬁguring proptosis.2
Patients with GO report feeling stared at by
others and socially isolated as a consequence of
their changed appearance3 and this has a
signiﬁcant impact on mood.4 There is also
growing evidence that GO has a detrimental
impact on vision-related daily functioning
including reading, watching TV, and driving.5–7
People with GO have been found to have a
poorer quality of life than patients with other
chronic conditions including diabetes,
emphysema, and heart failure.4,8 Although it is
important to establish the impact GO may have
on a patient’s well-being, it is equally important
to understand what factors explain how some
people live within normal levels of mood and
experience a better quality of life than others.
There is mixed evidence to support an
association between clinical factors and quality
of life in GO. For instance, although Park et al7
found that poorer quality of life was associated
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with more severe disease, including diplopia and dry
eyes, Kulig et al9 failed to replicate these ﬁndings either
before or after treatment for GO. Recent literature about
appearance and disﬁgurement has suggested signiﬁcant
variability amongst individuals with disﬁguring
conditions—with many adjusting positively to living with
a visible difference—and that psychological processes
rather than objective measurements can better explain this
variability in adjustment.10,11 In GO, Kahaly et al4 found
that depressive coping, trivialising the condition, and
higher levels of emotional distress were associated with
poorer physical and mental quality of life. However, other
psychosocial variables, identiﬁed within a framework for
adjustment to disﬁgurement as proposed by The
Appearance Research Collaboration,11 have not been
investigated within the GO population. The framework
suggests that a number of intervening cognitive processes,
individual to each patient, might help explain the quality of
life in people with a disﬁguring condition.
It was hypothesised that there will be large variation in
quality of life between individuals with GO, and that
intervening psychosocial processes would better explain
this variation than demographic or clinical factors.
Materials and methods
Participants
Patients were recruited from Moorﬁelds Eye Hospital,
London. Eligible patients aged 18 years or more with a
consultant-led diagnosis of GO, and having been listed for
orbital decompression surgery, were invited to participate in
the study by a researcher (SW). Patients were excluded if they
were considered by the consultant ophthalmologist to have
inadequate comprehension of written and spoken English, or
were suffering from psychiatric or co-morbid health
conditions that rendered them too ill or distressed to take part.
Study design
A prospective cross-sectional design was used.
Measures
Demographics Self-reported age, gender, marital status,
and ethnicity were collected.
Clinical measures The clinical measures assessed when
patients were listed for surgery included ophthalmic
disease duration, thyroid function, treatment history,
laterality of GO and planned surgery, smoking status,
upper and lower margin-reﬂex distance (MRD1 and
MRD2; mm), and the presence of corneal superﬁcial
punctate keratopathy, diplopia, and/or signs of hydraulic
orbital disease. Disease activity was measured using the
Clinical Activity Scale,12 a 10-item measure covering four
of the ﬁve classic signs of inﬂammation (pain, redness,
swelling, and impaired ocular function). Visual acuity
was measured for each eye using a Snellen Chart. This
was converted to the log of the minimal angle of
resolution, ranging between − 0.20 and 2.1, with a score of
2.2 assigned to patients with vision of counting ﬁngers or
worse. Optic neuropathy was identiﬁed using Ishihara
colour testing and the presence of a relative afferent
pupillary defect. Proptosis was measured using an Oculus
exophthalmometer (in mm), and the degree of asymmetry
gauged from the difference between each eye (in mm).
Psychosocial measures Self-report questionnaires were
completed by participants at the time they were listed for
surgery. The questionnaires chosen for this study were
based on a proposed framework of adjustment to GO
developed by the research team (Figure 1) adapted from
The Appearance Research Collaboration’s framework.11
Existing validated measures were used where possible,
and brief versions of questionnaires were adopted to
reduce participant burden.
Primary outcome measure Quality of life was measured
using the Australian version of Graves’ Ophthalmopathy
Quality of Life Questionnaire (GO-QOL).7 The GO-QOL
is made up of two subscales: ‘vision-related’ and
‘appearance-related’ quality of life.5 The GO-QOL has
been found to be a valid and reliable disease-speciﬁc
measure of quality of life with high internal consistency
(α= 0.86 for the visual function scale and α= 0.82 for the
appearance scale).13 Subscale scores were calculated by
following the questionnaire guidelines,13 and higher
scores on each subscale indicate better health-related
quality of life.
Socio-cognitive factors The Brief Fear of Negative
Evaluation scale14 was used to measure anxiety about
others’ opinions. This 12-item brief version correlates
highly with the original scale (α= 0.96), and higher scores
indicate a greater fear of negative evaluation from
others.
The Iowa-Netherlands Comparison Orientation
Measure15 measures how well respondents feel they are
doing in life when comparing him or herself with others.
This 11-item scale has been demonstrated to have good
internal consistency (α= 0.83), and higher scores indicate
a greater tendency to make social comparisons.
The Multidimensional Scale of Perceived Social
Support16 measures subjective levels of social support
from family, friends, and signiﬁcant others. The overall
scale has demonstrated good internal consistency
(α= 0.88) and test–retest reliability (r= 0.85).
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Higher scores on each 4-item subscale indicate greater
perceived social support.
Patient expectations of treatment Expectations of GO
surgery: In the absence of a GO-speciﬁc measure of a
patients’ expectations of treatment, an existing
questionnaire—the Expectations of Strabismus Surgery
Questionnaire17—was adapted with the items being
reviewed for relevance to GO. The 23-item questionnaire
assessed patients’ expectations in relation to three
domains: ‘appearance concerns’, ‘visual functioning’, and
‘intimacy and social relationships’. Participants were
instructed to rate how they expected surgery to change
these aspects of their lives, for instance ‘my vision’ on a
Likert scale from 1 (‘Made considerably worse’) to 5
(‘Considerably improve’). Higher scores indicate a greater
expectation for these areas to improve after surgery.
Appearance-speciﬁc cognitions The Derriford Appearance
Scale18 measures the impact of appearance-related
distress including social anxiety and avoidance. This
measure has demonstrated high internal consistency
(α= 0.92) and good test–retest reliability (r= 0.82), and
higher scores represent greater levels of appearance-
related distress and social avoidance.
The Valence and Salience of Appearance scales
(CARVAL & CARSAL)19 measure how an individual
evaluates his or her own physical appearance (CARVAL)
and the extent to which physical appearance is important
to the individual (CARSAL). Higher scores on each brief
measure indicate a more negative self-evaluation of
appearance and that greater value is placed on
appearance, respectively. Both questionnaires have
demonstrated high internal consistency (Pearson’s r
correlations between 0.72 and 0.84).
Perceived Visibility of GO: patients were asked to rate
how visible they felt their proptosis was to other people
on a 7-point Likert scale from 1 (‘Not at all visible’) to 7
(‘Extremely visible’).
Mood The Hospital Anxiety & Depression scale
(HADS)20 has been designed to screen for depression and
anxiety in patients with health problems. Higher total
subscale scores on this valid and reliable measure indicate
greater levels of anxious or depressed mood. Cut-off
scores were also applied to identify non-cases (0–7),
doubtful cases (8–10), and cases of possible clinical
anxiety or depression (scores of 11 and over).
Statistical analysis
Using G*Power (version 3.1.7, Franz Faul, Universitat Kiel,
Kiel, Germany), it was estimated that between 64 and 97
patients would be needed to achieve a power of 90% with
effect sizes of 0.45 and 0.9 for the GO-QOL appearance and
GO-QOL visual function subscales, respectively.13
All other statistical analyses were performed using IBM
SPSS 21 (IBM UK Ltd, Portsmouth, UK). Levels of missing
data, analysed using Little’s Missing Completely at
Random test, were shown to be Missing Completely at
Random (χ2= 7127, df= 8177, P= 1.000), with 11.9% of the
data missing at item level. Multiple imputation was
undertaken, and 10 imputed data sets were generated.
Scale scores for the psychosocial variables were re-
calculated and the analysis was conducted on all 10 data
sets and the results were pooled.
Univariate linear regressions were performed to
explore the relationship between each of the independent
variables and the GO-QOL subscale scores (dependent
variables). Hierarchical multiple regressions were
Figure 1 The potential variables to be used in hierarchical multiple regressions to explore factors associated with quality-of-life scores.
The framework is adapted from The Appearance Research Collaboration.11
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conducted using only the variables that were found to be
signiﬁcantly associated with each GO-QOL subscale. The
hierarchy used to enter the predictors into the regression
was based on the framework outlined in Figure 1.
Cohen’s f2 was used to calculate effect sizes for each of
these regressions.21 The variables were also examined for
multicollinearity, linearity, and homoscedasticity.
Multicollinearity was identiﬁed using VIF scores
provided in SPSS after each regression analysis, with
scores above 10 indicating multicollinearity.22 Histograms
and normal probability plots were assessed for linearity
and homoscedasticity.
Statement of ethics
Ethical approval was obtained from the North London
Research Ethics Committee (reference 11/H0724/6). We
certify that all applicable institutional and governmental
regulations concerning the ethical use of human
volunteers were followed during this research.
Results
Among 192 patients identiﬁed as eligible for the study,
135 (70%) agreed to take part, and 123 of the 135 enrolled
(91%) returned their questionnaire. Two participants’ data
were removed from analysis because of high proportions
of missing data (450%).
The descriptive characteristics of the study population
are shown in Table 1.
Summary statistics for the psychosocial variables are
shown in Table 2. Possible cases of clinical depression
were detected in 26% of patients, and 37% had possible
clinical levels of anxiety; 25 (21%) participants
experienced both. The large standard deviations for both
GO-QOL subscales indicate great variability in
adjustment from patient to patient.
Ten of the original 36 variables were signiﬁcantly
associated with the GO-QOL visual function subscale
using univariate analyses: age (F1,119= 16.6, Po0.001,
f2= 0.14), optic neuropathy (F1,119= 15.8, Po0.001,
f2= 0.15), log of the minimal angle of resolution
(F1,119= 15.6, Po0.001, f
2
= 0.12), previous
immunosuppression (F1,119= 11.1, P= 0.001, f
2
= 0.09),
asymmetrical GO (F1,119= 6.12, P= 0.015, f
2
= 0.05),
hydraulic orbit (F1,119= 9.22, P= 0.003, f
2
= 0.06), diplopia
(F1,119= 7.77, P= 0.006, f
2
= 0.07), Clinical Activity Scale
(F1,119= 6.22, P= 0.014, f
2
= 0.05), appearance-related
social anxiety and avoidance (F1,119= 3.95, P= 0.049,
f2= 0.06), anxiety (F1,119= 12.9, Po0.001, f
2
= 0.11), and
depression (F1,119= 41.6, Po0.001, f
2
= 0.36).
After entry of these variables into the model in the
order shown in Figure 1, 55% of the observed sample
variation in GO-QOL visual function score was accounted
for (R2= 0.55, F1,119= 9.89, Po0.001, f
2
= 0.8). Beta-
coefﬁcients indicated that age, asymmetrical GO, and
depression made signiﬁcant unique contributions to the
model, above other factors (Table 3).
Univariate analyses indicated that 13/36 variables were
signiﬁcantly associated with GO-QOL appearance: age
(F1,119= 5.42, P= 0.022, f
2
= 0.05), gender (F1,119= 8.13,
P= 0.005, f2= 0.07), previous surgery (F1,119= 5.55,
P= 0.020, f2= 0.06), family support (F1,119= 5.12, P= 0.025,
f2= 0.04), friends support (F1,119= 7.39, P= 0.008, f
2
= 0.06),
fear of negative evaluation (F1,119= 58.8, Po0.001, f
2
= 0.52),
Table 1 Demographic and clinical characteristics of the study
sample
Variable n (%) Range Mean± SD
Age (years) 22–79 47.1± 12.3
Gender
Male 33 (27)
Female 88 (73)
Ethnicity
Asian 11 (9.1)
White British/Irish/other 95 (78)
Black African/Caribbean/other 15 (12)
Relationship status
Married/living with partner 73 (60)
Single/other 48 (40)
Disease duration (months) 4–336 62.01± 42
Laterality of GO
Bilateral 101 (83)
Unilateral 20 (17)
Laterality of planned surgery
Bilateral 79 (65)
Unilateral 42 (35)
Treatment history
Previous immunosuppressants 58 (48)
Previous radiotherapy 18 (15)
Previous eyelid or orbital surgery 14 (12)
Thyroid function
Stable 106 (88)
Unstable 15 (12)
Visual acuity (LogMAR conversion)a 0–2 0.1± 0.4
Superﬁcial punctate keratopathy 39 (32)
Hydraulic orbital signs 25 (21)
Optic neuropathy 15 (12)
Diplopia 62 (51)
Marginal reﬂex distance 1 (mm)a 1.5–13 5.9± 2.1
Marginal reﬂex distance 2 (mm)a 4–11 6.7± 1.4
Exophthalmometry (mm)a 15–33 23.7± 2.7
Asymmetry (mm) 0–8 1.8± 1.8
Clinical activity score 0–9 1.12± 1.9
Smokers 38 (31)
aA worst eye analysis was conducted on these variables, based on the
amount of proptosis.
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social comparison (F1,119= 12.2, P= 0.001, f
2
= 0.11),
appearance-related social anxiety and avoidance
(F1,119= 60.0, Po0.001, f
2
= 0.59), salience of appearance
(F1,119= 64.6, Po0.001, f
2
= 0.51), valence of appearance
(F1,119= 98.9, Po0.001, f
2
= 0.76), perceived visibility
(F1,119= 27.5, Po0.001, f
2
= 0.24), anxiety (F1,119= 42.2,
Po0.001, f2= 0.39), and depression (F1,119= 70.5, Po0.001,
f2= 0.57).
After entry of the variables using the same model as
before, 75% of the observed sample variation in GO-
QOL appearance scores was accounted for (R2= 0.75,
F13,107= 20.7, Po0.001, f
2
= 2.3). Beta-coefﬁcients
indicated that gender, appearance-related social
anxiety and social avoidance, salience of appearance,
valence of appearance, perceived visibility of GO, and
depression all made signiﬁcant contributions to the
model (Table 4).
Discussion
This study investigated the factors that may be associated
with quality of life in patients with GO presenting for
orbital decompression surgery. It was found that being
older, having asymmetrical proptosis, and having higher
levels of depressed mood were associated with poorer
vision-related quality of life. Similarly, a greater value
being placed on appearance, a more negative evaluation
of appearance, greater perceived visibility of GO, and
having higher levels of depressed mood were all
associated with poorer appearance-related quality of life.
Participants in this study experienced levels of anxiety
and depression greater than the general population23 and
those living with other visibly disﬁguring conditions.24
GO-QOL visual function scores were comparable to
normative values established in a previous GO sample,13
but GO-QOL appearance scores were considerably lower.
These results suggest that, for many, the changed
appearance caused by GO has a greater impact and is
more debilitating than previously reported in the
literature.
Appearance-related quality of life was signiﬁcantly
associated with gender. For women, the eyes might be
regarded as central in perceived attractiveness, and
changes in ocular appearance could have a detrimental
inﬂuence on self-conﬁdence and willingness to appear in
photographs. Recent studies have suggested that women
with visible differences, including strabismus, may
experience higher levels of appearance-related distress
than men,25,26 which in turn could have an impact on
Table 2 Scores for the psychosocial measures at baseline for the
study sample
Variable Min Max Max possible Mean SD
GO-QOL appearance score 0 93.8 100 36.3 24.1
GOQOL visual function score 2.8 100 100 64.0 26.7
BFNE 14 60 60 38 9.2
INCOM 16 54 55 36 7.2
MSPSS family 4 20 20 15.3 4.5
MSPSS friends 4 20 20 15.2 4.2
MSPSS signiﬁcant other 4 20 20 15.6 5.2
CARSAL 5 30 30 25.2 4.7
CARVAL 11 48 48 38.7 8.4
DAS24 22 83 96 51.3 13
Men (n= 33) 22 83 96 50.7 15
Women (n= 88) 22 83 96 51.6 12
Visibility 1 7 7 5.7 1.5
HADS depression 1 21 21 9.2 4.9
HADS anxiety 0 19 21 7.6 4.7
Table 3 The ﬁnal step of a hierarchical multiple regression
model, with GO-QOL visual function score as the dependent
variable
B SE B t p
(Constant) 119.49 13.78 8.67 0.000**
Age − 0.50 0.19 − 2.63 0.009*
LogMAR − 11.28 6.45 − 1.75 0.080
CAS − 1.92 1.31 − 1.46 0.144
Asymmetry − 2.25 1.13 − 2.00 0.046*
Optic neuropathy − 4.09 9.54 − 0.43 0.669
Hydraulic orbit 2.55 6.47 0.39 0.694
Previous immunomodulation − 6.79 4.90 − 1.38 0.168
Diplopia − 4.39 4.29 − 1.02 0.307
DAS24 0.05 0.21 0.23 0.815
HADS anxiety − 0.69 0.58 − 1.20 0.231
HADS depression − 2.41 0.59 − 4.10 0.000**
*Po0.05, **Po0.001.
Table 4 The ﬁnal step of a hierarchical multiple regression
model, with GO-QOL appearance-related score as the dependent
variable
B SE B t P-value
(Constant) 132.09 13.84 9.55 0.000**
Age 0.11 0.11 0.94 0.346
Gender 6.56 3.02 2.17 0.03*
Previous surgery − 5.04 5.08 − 0.99 0.325
BFNE − 0.23 0.22 − 1.03 0.302
INCOM 0.01 0.23 0.06 0.950
MSPSS family − 0.29 0.34 − 0.87 0.382
MSPSS friends 0.56 0.37 1.53 0.127
DAS24 − 0.39 0.13 − 2.93 0.004*
CARSAL − 1.23 0.33 − 3.69 0.000**
CARVAL − 0.58 0.21 − 2.76 0.006*
Perceived visibility − 2.75 0.96 − 2.86 0.004*
HADS anxiety − 0.05 0.39 − 0.14 0.891
HADS depression − 1.12 0.43 − 2.60 0.009*
*Po0.05, **Po0.001.
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their quality of life in this domain. Furthermore, age was
found to be associated with vision-related quality of life,
which might reﬂect the greater disease severity often
found in older age.
Appearance-related cognitions were particularly
important in predicting appearance-related quality of life.
Increased social anxiety was associated with both poorer
vision-related and appearance-related quality of life in
this study, analogous to strabismus.27 Increased
importance of appearance-related information, as well as
having a poorer evaluation of one’s own appearance,
were also associated with quality of life in this sample.
Terwee et al28 found in a study investigating perceptions
of the severity of GO in different groups of observers and
patients themselves that clinicians tended to under-rate,
and patients over-rate, the severity of GO: This
emphasises the importance of eliciting a patient’s
perspective during pre-surgical assessment to improve
the chance of generating realistic patient expectations
about what surgery can achieve.
A limitation of the study is the cross-sectional design,
which does not enable causal direction to be established
and longitudinal studies that follow patients over time are
needed. If patients in this study were not euthyroid,
present hyper- or hypothyroidism could have affected
their quality of life. However, recent research found no
difference in the quality of life of people with thyroid
dysfunction compared with people with normal thyroid
levels,29 and it is possible that this may not have biased
the results of this study. It is also possible that quality of
life may predict mood in GO. However, mood has been
found to be a strong predictor of quality of life in
strabismus,24 supporting the current ﬁndings.
Furthermore, by exploring other factors that might
explain variance in quality of life in this population, rather
than examining quality of life and mood in isolation, this
study has expanded on previous studies and has
provided a new insight into the experiences of patients
with GO.
In conclusion, there was signiﬁcant variation in
quality of life in this sample, suggesting that some
people adjust successfully to living with GO, but for
others the impact is extreme. Contrary to conventional
medical perspectives, this variation was predominantly
accounted for by intervening cognitive processes, rather
than objective measures. There was, however, evidence
that older age and asymmetrical disease were associated
with poorer vision-related quality of life. The high
proportion of patients with potentially diagnosable
clinical depression and anxiety should be of concern to
clinicians, and it highlights the need for additional
psychosocial support.
Summary
What was known before
K Quality of life in Graves' orbitopathy is reduced owing to
changes in appearance and visual dysfunction. In other
disﬁguring conditions, a variety of psychological
processes have explained variation in quality of life.
What this study adds
K Identiﬁcation of psychological factors that are associated
with quality of life over and above clinical factors in
Graves' orbitopathy. The severity of the impact of Graves'
orbitopathy on mood.
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